Hypoparathyroidism is a rare hormonal disorder that requires lifelong management to restore calcium balance and prevent serious complications, with treatment options evolving from traditional supplements to innovative hormone replacement therapies currently being studied in clinical trials.

How We Care for Low Parathyroid Hormone Levels

When the tiny parathyroid glands in the neck stop working properly, the body faces a cascade of mineral imbalances that affect everything from muscles to nerves. The primary goal of treating hypoparathyroidism is to restore normal calcium levels in the blood and bring phosphorus back to healthy ranges. This approach helps control symptoms like muscle cramps, tingling sensations, and fatigue that can significantly impact daily life.

Treatment approaches vary depending on how severe the condition is, when symptoms began, and what caused the parathyroid glands to fail in the first place. For most people, the condition develops after neck or thyroid surgery, while others may have inherited forms or autoimmune causes. Each person’s treatment plan needs to be carefully tailored because calcium levels can fluctuate, and what works well for one patient might not suit another.

Standard treatments approved by medical societies have been used successfully for decades, primarily involving oral supplements to replace what the body cannot regulate on its own. However, researchers recognize that conventional therapy doesn’t perfectly replicate how healthy parathyroid glands work. That’s why exciting new therapies are being tested in clinical trials around the world, including replacement hormones that aim to restore the natural rhythm of calcium regulation rather than just treating the symptoms.

Established Treatment Methods

The foundation of hypoparathyroidism treatment has remained consistent for many years and centers on correcting the mineral imbalances caused by insufficient parathyroid hormone, which is the hormone that normally keeps calcium and phosphorus levels balanced. When parathyroid glands don’t produce enough of this hormone, calcium drops too low and phosphorus rises too high, creating an environment where muscles become irritable and nerves don’t function properly.

The first line of treatment involves oral calcium supplements, which patients take by mouth in the form of tablets, chewable pills, or liquid preparations. These supplements directly raise the amount of calcium circulating in the bloodstream. The doses are carefully adjusted based on blood tests, with the goal of maintaining calcium levels in the lower part of the normal range or just slightly below it. This target prevents symptoms without pushing levels too high, which could cause other problems like kidney stones.

Alongside calcium, patients receive high doses of vitamin D, which plays a crucial role in helping the body absorb calcium from food and supplements. The specific form prescribed is usually calcitriol, an activated form of vitamin D that works more directly than the over-the-counter supplements available at pharmacies. Calcitriol also helps the kidneys eliminate excess phosphorus from the body, addressing both sides of the mineral imbalance at once.

For patients who have low magnesium levels alongside their hypoparathyroidism, magnesium supplementation becomes necessary. Magnesium is essential because the parathyroid glands need adequate magnesium to release parathyroid hormone, and low magnesium can actually worsen calcium problems. Once magnesium is restored to normal, the body may respond better to calcium and vitamin D therapy.

In some cases where calcium levels remain stubbornly low despite standard supplements, doctors may add medications called thiazide diuretics. While these drugs are typically used to manage blood pressure, in hypoparathyroidism they help reduce the amount of calcium lost through urine, essentially helping the body hold onto more of the calcium it gets from supplements and diet.

Treatment duration is typically lifelong. Most patients need to continue taking supplements every single day to maintain stable calcium levels. The doses often need adjustment over time, especially during periods of illness, stress, or changes in diet. Regular blood tests every few months help doctors monitor calcium, phosphorus, and magnesium levels to ensure the treatment is working effectively.

Side effects from conventional therapy can include digestive problems, particularly constipation from calcium supplements. More concerning is the development of hypercalciuria, which means too much calcium spilling into the urine despite blood levels being controlled. This excessive urinary calcium increases the risk of kidney stones and can gradually damage kidney function over years. Some patients also develop calcium deposits in the brain, which may affect cognitive function and increase anxiety or depression.

Dietary adjustments complement supplement therapy. Patients are encouraged to eat foods naturally rich in calcium, such as dairy products, leafy green vegetables, soy products, and fortified foods. At the same time, they may be advised to reduce consumption of red meat and starchy foods like pasta and white bread, which can affect phosphorus levels and interfere with calcium absorption.

Innovative Therapies in Clinical Research

Recognizing that conventional treatment doesn’t fully restore normal physiology, researchers have spent years developing hormone replacement therapies that more closely mimic what healthy parathyroid glands do naturally. The concept is straightforward: instead of indirectly managing calcium with supplements, replace the missing parathyroid hormone itself. However, developing effective hormone replacement has proven challenging because the hormone needs to work steadily throughout the entire day and night.

One of the most significant breakthroughs comes from a therapy called palopegteriparatide, also known by its research name TransCon PTH. This treatment represents a new generation of parathyroid hormone replacement and has been approved in Europe, with approval expected in other countries including the United States. Palopegteriparatide is what scientists call a prodrug, meaning it’s designed to release active parathyroid hormone slowly and steadily over 24 hours after a single daily injection.

The way palopegteriparatide works is quite sophisticated. It consists of PTH(1-34), which is the active portion of parathyroid hormone, attached to a carrier molecule that keeps it inactive until the body gradually breaks the connection. As the bonds break naturally throughout the day, active hormone is released in a sustained manner, providing stable hormone levels rather than the peaks and valleys that come with older treatments. This continuous release pattern more closely resembles how healthy parathyroid glands naturally release hormone in response to calcium levels.

Clinical trials testing palopegteriparatide have shown promising results. In Phase 3 studies, which represent the final stage of testing before approval and involve large numbers of patients compared directly to standard treatment, researchers found remarkable success. After 26 weeks of treatment, approximately 79% of patients taking palopegteriparatide achieved normal calcium levels without needing any conventional supplements at all. In contrast, only 5% of patients receiving inactive placebo treatment reached normal calcium while continuing their regular supplements.

The benefits extended beyond just calcium levels. At 52 weeks, patients showed significant improvements in kidney function, with an average increase of over 9 units in their estimated glomerular filtration rate, which measures how well kidneys filter blood. This improvement is particularly important because conventional treatment often leads to kidney damage over time due to excessive calcium in urine. With palopegteriparatide, urinary calcium levels decreased, reducing the strain on kidneys and lowering the risk of kidney stones.

Perhaps most importantly for patients’ daily lives, those treated with palopegteriparatide reported improvements in their quality of life. This encompasses feeling less tired, having better mental clarity, experiencing fewer muscle symptoms, and generally being able to engage more fully in work, social activities, and family life. These subjective improvements matter enormously because they reflect how treatment affects real-world functioning, not just laboratory numbers.

An earlier parathyroid hormone replacement called rhPTH(1-84), marketed as Natpara, was available in the United States but faced manufacturing challenges. Small rubber fragments were discovered at injection sites in some patients, and despite efforts to resolve this quality control issue, the manufacturer announced in 2022 that production would cease globally. This situation highlights the technical challenges of manufacturing complex hormone therapies safely and consistently.

The short-acting version of parathyroid hormone, PTH(1-84), had been tested extensively but showed mixed results in clinical trials. While it could improve calcium levels, its short duration of action meant levels fluctuated significantly between doses. Patients typically needed to inject it twice daily, and the hormone’s effects wore off quickly, leading to inconsistent symptom control. This experience taught researchers that sustained, steady hormone levels were essential for truly effective treatment.

Research continues with other innovative molecules. Eneboparatide represents another approach to long-acting parathyroid hormone replacement and is currently being evaluated in Phase 3 clinical trials. While specific details about its mechanism differ from palopegteriparatide, it similarly aims to provide consistent hormone activity throughout the day.

For patients with a specific genetic form of the condition called autosomal dominant hypocalcemia type 1, scientists are testing a completely different approach. A medication called encaleret, which is classified as a calcilytic, works by modifying how calcium sensors in the body respond to calcium levels. This treatment doesn’t replace parathyroid hormone but instead adjusts the body’s sensitivity to calcium signals, potentially allowing the parathyroid glands to work more effectively even when they’re impaired.

Clinical trials for these newer therapies typically recruit patients who have chronic hypoparathyroidism and aren’t adequately controlled with conventional treatment, or who develop complications like kidney problems or persistent symptoms despite optimized supplement doses. Trials are conducted across multiple countries, including locations in the United States, Europe, and other regions, making these experimental treatments accessible to patients in various geographic areas.

The phases of clinical trials serve different purposes. Phase 1 trials, usually involving small numbers of healthy volunteers or patients, primarily assess safety and determine appropriate dose ranges. Phase 2 trials enroll more patients to evaluate whether the treatment effectively improves the condition being studied. Phase 3 trials are large-scale studies that compare the new treatment directly against current standard therapy or placebo, providing definitive evidence about effectiveness and safety that regulatory agencies need for approval decisions.

Most common treatment methods

• Oral calcium supplementation
  • Taken as tablets, chewable preparations, or liquid forms to directly raise blood calcium levels
  • Doses carefully adjusted based on regular blood test monitoring
  • Target is to maintain calcium in the lower normal range to prevent symptoms without causing complications
  • May cause constipation as a side effect, particularly at higher doses
• Active vitamin D therapy
  • Prescription form called calcitriol, which is more potent than over-the-counter vitamin D
  • Helps the body absorb calcium from food and supplements in the intestines
  • Assists kidneys in eliminating excess phosphorus from the bloodstream
  • Requires different dosing than standard vitamin D supplements available without prescription
• Magnesium supplementation
  • Used when blood magnesium levels are found to be low alongside calcium problems
  • Essential because parathyroid glands need adequate magnesium to function properly
  • Helps improve the body’s response to calcium and vitamin D therapy
• Thiazide diuretic medications
  • Added to treatment when calcium levels remain low despite standard supplements
  • Reduce the amount of calcium lost through urine
  • Help the body retain more calcium from dietary sources and supplements
• Hormone replacement therapy
  • Palopegteriparatide (TransCon PTH) provides sustained release of active parathyroid hormone over 24 hours
  • Administered as once-daily subcutaneous injection
  • Can eliminate need for conventional calcium and vitamin D supplements in many patients
  • Reduces urinary calcium excretion and improves kidney function
  • Approved in Europe and under review in other countries
• Emergency intravenous calcium
  • Used when calcium drops to dangerously low levels causing seizures or severe symptoms
  • Given through a tube inserted into a vein in hospital settings
  • Provides rapid correction of life-threatening hypocalcemia
  • Continued until calcium levels stabilize and patient can safely transition to oral therapy